美国城市中无家可归的注射吸毒者被非自愿驱离的人群健康效应
该研究采用封闭队列微观模拟模型,模拟美国23个城市中无家可归的注射吸毒者注射吸毒的自然史和健康结局,模型数据来自美国疾病控制与预防中心国家HIV行为监测系统的城市级数据和已发表数据。比较「无驱离」与「持续非自愿驱离」两种情景,预测10年内的过量死亡、严重注射相关感染及其死亡、住院、阿片类使用障碍药物启动和生存年数。结果显示,持续非自愿驱离情景下,每万人10年内估计增加974至2175例过量死亡、611至1360例住院、减少3140至8812例阿片类使用障碍药物启动;持续非自愿驱离可能贡献15.6%至24.4%的额外死亡。作者认为,非自愿驱离可能大幅增加药物相关发病和死亡,对驱离实践以及住房和支持服务可及性等政策具有意义。
要点
- 在23个美国城市无家可归的注射吸毒者中,持续非自愿驱离 vs 无驱离,10年内每万人估计增加974至2175例过量死亡。
- 持续非自愿驱离 vs 无驱离,每万人估计增加611至1360例因注射相关严重感染的住院。
- 持续非自愿驱离 vs 无驱离,每万人估计减少3140至8812例阿片类使用障碍药物的启动。
- 持续非自愿驱离可能贡献10年内无家可归的注射吸毒者额外死亡的15.6%至24.4%。
- 作者认为,非自愿驱离可能大幅增加药物相关发病和死亡,对驱离实践及住房和支持服务政策具有意义。
适用人群与场景
- 美国23个城市中无家可归的注射吸毒者,模型队列基于美国疾病控制与预防中心国家HIV行为监测系统的城市级数据和已发表数据构建。
研究设计与关键结果
- 研究设计为封闭队列微观模拟模型,模拟美国23个城市中无家可归的注射吸毒者注射吸毒的自然史和健康结局,比较「无驱离」与「持续非自愿驱离」两种情景10年内的结局。
- 持续非自愿驱离 vs 无驱离,10年内每万人估计增加974至2175例过量死亡。
- 持续非自愿驱离 vs 无驱离,每万人估计增加611至1360例因注射相关严重感染的住院。
- 持续非自愿驱离 vs 无驱离,每万人估计减少3140至8812例阿片类使用障碍药物的启动。
- 持续非自愿驱离可能贡献10年内无家可归的注射吸毒者额外死亡的15.6%至24.4%。
证据类型、等级与局限
- 证据类型:封闭队列微观模拟模型研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,非自愿驱离可能大幅增加药物相关发病和死亡;这些发现对驱离实践以及住房和支持服务可及性等政策具有意义,这些政策可能减轻相关危害。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: At least 500 000 people in the US experience homelessness nightly. More than 30% of people experiencing homelessness also have a substance use disorder. Involuntary displacement is a common practice in responding to unsheltered people experiencing homelessness. Understanding the health implications of displacement (eg, "sweeps," "clearings," "cleanups") is important, especially as they relate to key substance use disorder outcomes.
OBJECTIVE: To estimate the long-term health effects of involuntary displacement of people experiencing homelessness who inject drugs in 23 US cities.
DESIGN, SETTING, AND PARTICIPANTS: A closed cohort microsimulation model that simulates the natural history of injection drug use and health outcomes among people experiencing homelessness who inject drugs in 23 US cities. The model was populated with city-level data from the Centers for Disease Control and Prevention's National HIV Behavioral Surveillance system and published data to make representative cohorts of people experiencing homelessness who inject drugs in those cities.
MAIN OUTCOMES AND MEASURES: Projected outcomes included overdose mortality, serious injection-related infections and mortality related to serious injection-related infections, hospitalizations, initiations of medications for opioid use disorder, and life-years lived over a 10-year period for 2 scenarios: "no displacement" and "continual involuntary displacement." The population-attributable fraction of continual displacement to mortality was estimated among this population.
RESULTS: Models estimated between 974 and 2175 additional overdose deaths per 10 000 people experiencing homelessness at 10 years in scenarios in which people experiencing homelessness who inject drugs were continually involuntarily displaced compared with no displacement. Between 611 and 1360 additional people experiencing homelessness who inject drugs per 10 000 people were estimated to be hospitalized with continual involuntary displacement, and there will be an estimated 3140 to 8812 fewer initiations of medications for opioid use disorder per 10 000 people. Continual involuntary displacement may contribute to between 15.6% and 24.4% of additional deaths among unsheltered people experiencing homelessness who inject drugs over a 10-year period.
CONCLUSION AND RELEVANCE: Involuntary displacement of people experiencing homelessness may substantially increase drug-related morbidity and mortality. These findings have implications for the practice of involuntary displacement, as well as policies such as access to housing and supportive services, that could mitigate these harms.
参考来源
- Barocas JA, Nall SK, Axelrath S, et al. Population-Level Health Effects of Involuntary Displacement of People Experiencing Unsheltered Homelessness Who Inject Drugs in US Cities. JAMA. 2023. PMID: 37036716. doi:10.1001/jama.2023.4800
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。